Guo Yu1, Zakir Ali2, Anam Sajjad Khan2, Kalim Ullah3, Humzah Jamshaid2, Alam Zeb4, Muhammad Imran4, Sadia Sarwar4, Han-Gon Choi5, Fakhar Ud Din2. 1. Department of Head and Neck Breast, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang City, Henan Province, 453000, People's Republic of China. 2. Nanomedicine Research Group, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 45320, Pakistan. 3. Department of Zoology, Kohat University of Science & Technology, Kohat, Khyber Pakhtunkhwa, Pakistan. 4. Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan. 5. College of Pharmacy & Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, South Korea.
Abstract
BACKGROUND: The purpose of this study was to investigate the suitability of nanostructured lipid carriers (NLCs) loaded with miltefosine (HePC) as an anticancer drug for the treatment of breast cancer. METHODS: HePC-NLCs were prepared using a microemulsion technique and then evaluated for particle size, polydispersity index (PDI), incorporation efficiency, in vitro release of entrapped drug, and hemolytic potential. Furthermore, pharmacokinetic, biodistribution, and liver toxicity analyses were performed in Sprague-Dawley rats, and antitumor efficacy was evaluated in Michigan Cancer Foundation-7 (MCF-7) and squamous cell carcinoma-7 (SCC-7) cells in vitro and in tumour-bearing BALB/c mice in vivo. Advanced analyses including survival rate, immunohistopathology, and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays were performed to evaluate apoptosis in vivo. RESULTS: The average particle size of the HePC-NLCs was 143 ± 16 nm, with a narrow PDI (0.104 ± 0.002), and the incorporation efficiency was found to be 91 ± 7%. The NLCs released HePC in a sustained manner, and this release was significantly lower than that of free drug. The in vitro hemolytic assay demonstrated a significantly reduced hemolytic potential (~9%) of the NLCs compared to that of the test formulations. The HePC-NLCs demonstrated enhanced pharmacokinetic behaviour over free drug, including extended blood circulation and an abridged clearance rate in rats. Furthermore, the HePC-NLCs exhibited higher cytotoxicity than the free drug in MCF-7 and SCC-7 cells. Moreover, the HePC-NLCs showed significantly enhanced (P < 0.005) antitumor activity compared to that of the control and free drug-treated mouse groups. Tumour cell apoptosis was also confirmed, indicating the antitumor potential of the HePC-NLCs. CONCLUSION: These findings demonstrate the ability of NLCs as a drug delivery system for enhanced pharmacokinetic, antitumor, and apoptotic effects, most importantly when loaded with HePC.
BACKGROUND: The purpose of this study was to investigate the suitability of nanostructured lipid carriers (NLCs) loaded with miltefosine (HePC) as an anticancer drug for the treatment of breast cancer. METHODS: HePC-NLCs were prepared using a microemulsion technique and then evaluated for particle size, polydispersity index (PDI), incorporation efficiency, in vitro release of entrapped drug, and hemolytic potential. Furthermore, pharmacokinetic, biodistribution, and liver toxicity analyses were performed in Sprague-Dawley rats, and antitumor efficacy was evaluated in Michigan Cancer Foundation-7 (MCF-7) and squamous cell carcinoma-7 (SCC-7) cells in vitro and in tumour-bearing BALB/c mice in vivo. Advanced analyses including survival rate, immunohistopathology, and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays were performed to evaluate apoptosis in vivo. RESULTS: The average particle size of the HePC-NLCs was 143 ± 16 nm, with a narrow PDI (0.104 ± 0.002), and the incorporation efficiency was found to be 91 ± 7%. The NLCs released HePC in a sustained manner, and this release was significantly lower than that of free drug. The in vitro hemolytic assay demonstrated a significantly reduced hemolytic potential (~9%) of the NLCs compared to that of the test formulations. The HePC-NLCs demonstrated enhanced pharmacokinetic behaviour over free drug, including extended blood circulation and an abridged clearance rate in rats. Furthermore, the HePC-NLCs exhibited higher cytotoxicity than the free drug in MCF-7 and SCC-7 cells. Moreover, the HePC-NLCs showed significantly enhanced (P < 0.005) antitumor activity compared to that of the control and free drug-treated mouse groups. Tumour cell apoptosis was also confirmed, indicating the antitumor potential of the HePC-NLCs. CONCLUSION: These findings demonstrate the ability of NLCs as a drug delivery system for enhanced pharmacokinetic, antitumor, and apoptotic effects, most importantly when loaded with HePC.
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Mohammed Elmowafy; Hany M Ibrahim; Mohammed A Ahmed; Khaled Shalaby; Ayman Salama; Hossam Hefesha Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419
Authors: Maria Mir; Saba Ishtiaq; Samreen Rabia; Maryam Khatoon; Ahmad Zeb; Gul Majid Khan; Asim Ur Rehman; Fakhar Ud Din Journal: Nanoscale Res Lett Date: 2017-08-17 Impact factor: 4.703
Authors: Evandro Fei Fang; Chris Zhi Yi Zhang; Lin Zhang; Jack Ho Wong; Yau Sang Chan; Wen Liang Pan; Xiu Li Dan; Cui Ming Yin; Chi Hin Cho; Tzi Bun Ng Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240
Authors: R Xing; O Mustapha; T Ali; M Rehman; S S Zaidi; A Baseer; S Batool; M Mukhtiar; S Shafique; M Malik; S Sohail; Z Ali; F Zahid; A Zeb; F Shah; A Yousaf; F Din Journal: Biomed Res Int Date: 2021-07-03 Impact factor: 3.411